HOUSTON — Bruton's tyrosine kinase inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have revolutionized the ...

One of the world's top biopharma companies, AbbVie (NYSE: ABBV) is a fairly complicated stock to approach as an independent investor. Aside from the scientific chops needed to evaluate the quality ...

Ibrutinib is under clinical development by AbbVie and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase II drugs for Acute ...

AbbVie Inc. (NYSE:ABBV), a global biopharmaceutical company, develops and sells prescription medications for various health conditions, focusing on chronic autoimmune diseases, oncology ...

AbbVie stock (NYSE: ABBV) has more than doubled in value since early January 2021 – jumping from levels of $90 then to around $195 now – vs. an increase of about 50% for the S&P 500 over this ...

In this article, we are going to take a look at where AbbVie Inc (NYSE:ABBV) stands against the other 52-week high stocks. The U.S. stock market has been on a roll, with major indices clocking ...

For instance, the price of AbbVie Inc. (NYSE:ABBV) stock is up an impressive 190% over the last five years. On top of that, the share price is up 22% in about a quarter. This could be related to ...

AbbVie delivered Y/Y growth in the second quarter despite Humira’s decline, with Skyrizi and Rinvoq as key growth drivers, achieving 45% and 56% Y/Y growth, respectively. I expect Skyrizi to ...

AbbVie's Qulipta gains ground with docs for migraine prevention, as pharma looks to pressure Biohaven's Nurtec The top-selling CGRP is Pfizer’s Nurtec, which rang up sales of $928 million last year.